Aura Biosciences, Inc. Gain (Loss) on Termination of Lease
Aura Biosciences, Inc. (AURA) reported Gain (Loss) on Termination of Lease of -$296.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-27.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnTerminationOfLease · last filed 2024-03-27
- Aura Biosciences, Inc. gain (loss) on termination of lease for fiscal 2022 was -$296.00K.
| Period end | Gain (Loss) on Termination of Lease 12 month |
|---|---|
| 2022-12-31 | -$296.00K 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |